What are Ozempic and Mounjaro?
Ozempic (semaglutide) and Mounjaro (tirzepatide) are two of the most talked-about GLP-1 medications on the market in 2026. Both are injectable medications, but they work in slightly different ways and come from different manufacturers.
Ozempic (semaglutide, made by Novo Nordisk) was originally approved for type 2 diabetes management but has become widely used off-label for weight loss. It's a GLP-1 receptor agonist — meaning it mimics the glucagon-like peptide-1 hormone. Wegovy is the FDA-approved weight loss version at higher doses. Both are delivered as weekly injections.
Mounjaro (tirzepatide, made by Eli Lilly) is a dual GIP/GLP-1 receptor agonist, which is a key difference. This means it targets two hormones instead of one. Zepbound is the FDA-approved weight loss version. Like Ozempic, it's administered weekly via injection.
Important note: This is an informational comparison. Always consult your healthcare provider for medical decisions about which medication is right for you.
How They Work: Single vs Dual Hormone
Understanding the mechanism of action helps explain why these medications work differently for different people.
Semaglutide (Ozempic/Wegovy): This medication works by mimicking the GLP-1 hormone, which does three main things: slows gastric emptying (meaning food stays in your stomach longer), reduces appetite by signaling to your brain, and improves your body's insulin sensitivity. This single-hormone approach has been proven effective and has the longest track record in clinical use.
Tirzepatide (Mounjaro/Zepbound): This medication takes a different approach by mimicking both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) hormones. The dual mechanism may explain why some studies show greater weight loss with tirzepatide. By targeting two hormonal pathways, it may provide additional metabolic benefits and potentially greater appetite suppression.
Both medications reduce appetite and slow digestion, but the theoretical advantage of tirzepatide's dual action may translate to better results for some people. However, individual response varies significantly.
Weight Loss: What the Studies Show
Clinical trial data shows how these medications perform in real-world conditions, though individual results will vary.
Ozempic/Wegovy: The STEP trials (the gold standard for weight loss studies) showed approximately 15-17% body weight loss over 68 weeks at the highest dose (2.4mg weekly). These results were impressive and represented a major breakthrough when first published. Many people achieved significant weight loss, with improvements in metabolic health markers.
Mounjaro/Zepbound: The SURMOUNT trials showed approximately 20-22% body weight loss over 72 weeks at the highest dose (15mg weekly). This represents a meaningful difference from semaglutide results. Head-to-head comparisons in clinical studies consistently show tirzepatide achieving greater weight loss than semaglutide.
Important caveat: Individual results vary significantly. Some people respond better to one medication than the other. Factors like your starting weight, metabolism, adherence, diet, exercise, and individual body chemistry all influence outcomes. The average results don't guarantee your personal results.
Dosing Schedules Compared
Both medications use a dose escalation approach, starting low and gradually increasing. Here's how they compare:
| Week | Ozempic (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|
| 1–4 | 0.25 mg/week | 2.5 mg/week |
| 5–8 | 0.5 mg/week | 5 mg/week |
| 9+ | 1 mg/week (maintenance) | 7.5 mg/week |
| Optional | 2 mg/week | 10 mg → 12.5 mg → 15 mg/week |
Key differences: Both are weekly injections, which is convenient. Mounjaro has more dose steps (up to 6 escalation points), allowing for more gradual titration. This can be helpful for managing side effects. Ozempic reaches maintenance dosing faster with fewer escalation steps.
Tracking your dose schedule matters. Using a tool like Peptide Plus can help you set reminders for dose escalation and never miss a timing window for increasing your dose.
Side Effects Comparison
Side effects are an important consideration when choosing a GLP-1 medication. Both medications have similar side effect profiles, though the severity and timing vary by individual.
Common to both medications:
- Nausea (most common)
- Diarrhea or constipation
- Injection site reactions (mild redness, itching)
- Decreased appetite (this is actually the mechanism, but it can feel extreme initially)
- Vomiting (less common)
Ozempic side effects from clinical trials: Approximately 44% of people reported nausea and roughly 30% reported diarrhea. Side effects were typically worse during the dose escalation phases.
Mounjaro side effects from clinical trials: Similar rates overall, though some studies suggest slightly lower nausea with tirzepatide (around 35-40%). The dual mechanism hasn't produced significantly different side effect profiles.
Important pattern: For both medications, side effects are typically worst during dose escalation weeks and improve over time as your body adjusts. Most people find side effects manageable after the first 2-3 weeks at each dose level.
Rare but serious concerns (both medications): Both carry black box warnings from the FDA regarding potential thyroid issues and pancreatitis risk. Both also carry warnings about gallbladder complications. These are serious but rare. If you experience severe abdominal pain, contact your healthcare provider immediately.
For a detailed guide on managing common side effects, see our article on Managing GLP-1 Side Effects.
Cost and Availability in 2026
Cost is often the deciding factor for many people when choosing between medications.
Without insurance: Both Ozempic and Mounjaro are expensive. Expect to pay approximately €800–1200 per month out-of-pocket if you don't have insurance coverage. This is a significant financial commitment.
Insurance coverage varies significantly. Some insurance plans cover weight loss use of these medications, others don't. Some require prior authorization or step therapy (trying other medications first). You'll need to check with your specific insurance provider.
Generic/biosimilar options: Generic versions and biosimilar semaglutide are starting to appear in some markets, which may reduce costs. Biosimilars for tirzepatide are still in development but may arrive later in 2026 or 2027.
The oral option game-changer: Wegovy (oral semaglutide) was approved by the FDA in December 2025 and launched in January 2026. This 50mg daily pill offers comparable effectiveness to injections without the needle. This is changing the landscape for weight loss treatment. Some people prefer pills to injections, and availability of an oral option increases choice.
In Europe and Ireland: Availability and pricing differ from the US. Some regions have better insurance coverage, others have different out-of-pocket costs. Check with local healthcare providers or pharmacies for regional pricing.
New in 2026: The Oral Option
The December 2025 FDA approval of Wegovy as an oral pill (50mg semaglutide) marks a significant shift in GLP-1 treatment.
Oral Wegovy (semaglutide pill): Studies show comparable effectiveness to the injection form. Taking a daily pill appeals to people who dislike injections. No prescription pens, no injection sites, no worried about proper injection technique. Just a daily pill with water.
Mounjaro oral version: No oral version of tirzepatide is available yet. Eli Lilly is developing an oral tirzepatide, but it's not yet approved. If you prefer a pill format, Wegovy oral is currently your only FDA-approved GLP-1 option in pill form.
For many people, the choice between weekly injection and daily pill is simply a matter of personal preference. Weekly injections offer "set it and forget it" convenience; daily pills offer no needles but require daily adherence.
Which One Should You Choose?
There's no universally correct answer. The "better" medication depends on your individual circumstances:
Consider Ozempic/Wegovy if:
You want a longer track record (semaglutide has been used longer and has more real-world data), prefer not to escalate through many dose levels, or want the option of an oral pill (Wegovy). It's also typically slightly cheaper and more widely available in some regions.
Consider Mounjaro/Zepbound if:
Clinical data suggests you might benefit from greater weight loss (20-22% vs 15-17%), you prefer gradual dose escalation over more steps, or you want to try the dual GLP-1/GIP mechanism. Some people respond better to the tirzepatide approach.
Many people start with one medication and, if it's not working well, switch to the other. Your doctor can guide this decision based on your health history, other medications, and treatment goals.
Closing Thoughts
Whether you choose Ozempic, Wegovy, Mounjaro, Zepbound, or another GLP-1 medication, tracking your journey makes a real difference. Logging your doses, monitoring side effects, and tracking your nutrition helps you and your healthcare provider make better decisions over time.
Peptide Plus supports all GLP-1 medications — Ozempic, Wegovy, Mounjaro, Zepbound, and more. Track doses, log side effects, scan meals, and export reports for your doctor. Try it free for 7 days. No credit card required. Download Peptide Plus →